Host fate is rapidly determined by innate effector-microbial interactions during acinetobacter baumannii bacteremia

Journal of Infectious Diseases

Volumn 211, Issue 8, 2015, Pages 1296-1305

  Bruhn, Kevin W ^a   Pantapalangkoor, Paul ^a   Nielsen, Travis ^a   Tan, Brandon ^a   Junus, Justin ^a   Hujer, Kristine M ^d,f   Wright, Meredith S ^c   Bonomo, Robert A ^d,e,f   Adams, Mark D ^c   Chen, Wangxue ^g   Spellberg, Brad ^b  

^a Department of Molecular Microbiology and Immunology ^*  (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c J CRAIG VENTER INSTITUTE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^g NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Acinetobacter baumannii; bloodstream; mouse; pathogenesis; virulence

Indexed keywords

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTEREMIA; BACTERIAL CLEARANCE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CELL TRANSPORT; CONTROLLED STUDY; GROWTH RATE; HOST PATHOGEN INTERACTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; INOCULATION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; ACINETOBACTER INFECTION; ANIMAL; C3H MOUSE; IMMUNOLOGY; MACROPHAGE; MICROBIOLOGY; MULTIDRUG RESISTANCE; NEUTROPHIL; ORGANISMAL INTERACTION; VIRULENCE;

ANTIINFECTIVE AGENT; VIRULENCE FACTOR;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; IMMUNITY, INNATE; MACROPHAGES; MICE; MICE, INBRED C3H; MICROBIAL INTERACTIONS; NEUTROPHILS; VIRULENCE; VIRULENCE FACTORS;

EID: 84926609513     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu593     Document Type: Article

References (35)

1. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51:3471-84.
2. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008; 46:1254-63.
3. McGowan JE Jr. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Med 2006; 119(6 suppl 1): S29-36; discussion S62-70.
4. Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006; 43(suppl 2):S43-8.
5. Spellberg B, Blaser M, Guidos R, et al. Infectious Diseases Society of America. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 2011; 52(suppl 5):S397-428.
6. Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:155-64.
7. Park YK, Peck KR, Cheong HS, Chung DR, Song JH, Ko KS. Extreme drug resistance in Acinetobacter baumannii infections in intensive care units, South Korea. Emerg Infect Dis 2009; 15:1325-7.
8. Tseng YC, Wang JT, Wu FL, Chen YC, Chie WC, Chang SC. Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2007; 59:181-90.
9. Metan G, Sariguzel F, Sumerkan B. Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia. Eur J Intern Med 2009; 20:540-4.
10. Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009; 63:775-80.
11. Munoz-Price LS, Zembower T, Penugonda S, et al. Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: study of a 2-state monoclonal outbreak. Infect Cont Hosp Epidemiol 2010; 31:1057-62.
12. Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the clinical pipeline in 2013. J Antibiot (Tokyo) 2013; 66:571-91.
13. Doughari HJ, Ndakidemi PA, Human IS, Benade S. The ecology, biology and pathogenesis of Acinetobacter spp.: an overview. Microbes Environ 2011; 26:101-12.
14. Perez F, Ponce-Terashima R, Adams MD, Bonomo RA. Are we closing in on an "elusive enemy"? the current status of our battle with Acinetobacter baumannii. Virulence 2011; 2:86-90.
15. Russo TA, Luke NR, Beanan JM, et al. The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor. Infect Immun 2010; 78:3993-4000.
16. Jacobs AC, Hood I, Boyd KL, et al. Inactivation of phospholipase D diminishes Acinetobacter baumannii pathogenesis. Infect Immun 2010; 78:1952-62.
17. van Faassen H, KuoLee R, Harris G, Zhao X, Conlan JW, Chen W. Neutrophils play an important role in host resistance to respiratory infection with Acinetobacter baumannii in mice. Infect Immun 2007; 75:5597-608.
18. Qiu H, Kuolee R, Harris G, Chen W. Role of NADPH phagocyte oxidase in host defense against acute respiratory Acinetobacter baumannii infection in mice. Infect Immun 2009; 77:1015-21.
19. Qiu H, Kuolee R, Harris G, Van Rooijen N, Patel GB, Chen W. Role of macrophages in early host resistance to respiratory Acinetobacter baumannii infection. PLoS One 2012; 7:e40019.
20. Lin L, Tan B, Pantapalangkoor P, et al. Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. MBio 2012; 3:e00312-12.
21. Luo G, Lin L, Ibrahim AS, et al. Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection. PLoS One 2012; 7:e29446.
22. Harris G, Kuo Lee R, Lam CK, et al. A mouse model of Acinetobacter baumannii-associated pneumonia using a clinically isolated hyperviru-lent strain. Antimicrob Agents Chemother 2013; 57:3601-13.
23. Valentine SC, Contreras D, Tan S, Real LJ, Chu S, Xu HH. Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County, California. J Clin Microbiol 2008; 46:2499-507.
24. Arroyo LA, Herrera CM, Fernandez L, Hankins JV, Trent MS, Hancock RE. The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoe-thanolamine modification of lipid A. Antimicrob Agents Chemother 2011; 55:3743-51.
25. Hujer KM, Hujer AM, Hulten EA, et al. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother 2006; 50:4114-23.
26. Piechaud M, Second L. Studies of 26 strains of Moraxella Iwoffi. Ann Inst Pasteur (Paris) 1951; 80:97-9.
27. Jacobs AC, Thompson MG, Black CC, et al. AB5075, a highly virulent isolate of Acinetobacter baumannii, as a model strain for the evaluation of pathogenesis and antimicrobial treatments. MBio 2014; 5:e01076-14.
28. Ecker JA, Massire C, Hall TA, et al. Identification of Acinetobacter species and genotyping of Acinetobacter baumannii by multilocus PCR and mass spectrometry. J Clin Microbiol 2006; 44:2921-32.
29. Wright MS, Haft DH, Harkins DM, et al. New insights into dissemination and variation of the health care-associated pathogen Acinetobacter baumannii from genomic analysis. MBio 2014; 5:e00963-13.
30. Diancourt L, Passet V, Nemec A, Dijkshoorn L, Brisse S. The population structure of Acinetobacter baumannii: expanding multiresistant clones from an ancestral susceptible genetic pool. PLoS One 2010; 5:e10034.
31. Vogel CW, Smith CA, Muller-Eberhard HJ. Cobra venom factor: structural homology with the third component of human complement. Journal of immunology 1984; 133:3235-41.
32. Morgan BP, Olavesen MG, Watts MJ. Presence of a membrane attack complex inhibiting protein on the human epithelial cell line HeLa. Biochemical Society transactions 1990; 18:673-4.
33. Biewenga J, van der Ende MB, Krist LF, Borst A, Ghufron M, van Rooijen N. Macrophage depletion in the rat after intraperitoneal administration of liposome-encapsulated clodronate: depletion kinetics and accelerated repopulation of peritoneal and omental macrophages by administration of Freund's adjuvant. Cell and tissue research 1995; 280:189-96.
34. Fraser CC, Chen BP, Webb S, van Rooijen N, Kraal G. Circulation of human hematopoietic cells in severe combined immunodeficient mice after Cl2MDP-liposome-mediated macrophage depletion. Blood 1995; 86:183-92.
35. Lin L, Tan B, Pantapalangkoor P, et al. Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodomi-nant epitopes. Vaccine 2013; 31:313-8.